•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
OpenAI has introduced GPT-Rosalind, an artificial intelligence model designed specifically for scientific research and drug discovery, the company said in a press release dated Thursday, April 16. OpenAI said the model features improved tool use and a deeper understanding of chemistry, protein engineering and genomics.
OpenAI said GPT-Rosalind is intended to help scientists address constraints in complex research workflows and reduce the time required to move a new drug from target discovery to regulatory approval. The company cited a timeline of 10 to 15 years for that process.
OpenAI added that advanced AI systems can help researchers move through these workflows faster by not only improving efficiency, but also by enabling scientists to explore more possibilities, surface connections that might otherwise be missed, and arrive at better hypotheses sooner.
OpenAI is offering GPT-Rosalind as a research preview in ChatGPT, Codex and via the API for qualified customers through the company’s trusted access program.
The company also introduced a Life Sciences research plugin for Codex. OpenAI said the plugin is freely accessible and helps scientists connect models to more than 50 scientific tools and data sources.
OpenAI said it is working with customers including Amgen, Moderna, the Allen Institute and Thermo Fisher Scientific to apply GPT-Rosalind in research and discovery.
Sean Bruich, senior vice president of artificial intelligence and data at Amgen, said in the release: “Our unique collaboration with OpenAI enables us to apply their most advanced capabilities and tools in new and innovative ways with the potential to accelerate how we deliver medicines to patients.”
A PYMNTS Intelligence report, “Generative AI Can Elevate Health and Revolutionize Healthcare,” said generative AI innovations can expand researchers’ capabilities and accelerate drug discovery and diagnostics.
The article also referenced earlier reporting that pharmaceutical companies are reshaping operating models around AI to speed clinical trials and regulatory submissions. It further noted that AI is being applied across drug discovery, clinical strategy and manufacturing optimization.
In March, pharmaceutical company Lilly was reported to have signed a $2.75 billion deal with Insilico Medicine to use AI to accelerate the discovery and development of novel therapeutics.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
